$11.73
2.82% yesterday
Nasdaq, Jul 21, 10:00 pm CET
ISIN
US4884451075
Symbol
ZVRA
Sector
Industry

KemPharm, Inc. Stock price

$11.73
+2.73 30.33% 1M
+3.58 43.93% 6M
+3.39 40.65% YTD
+5.39 85.02% 1Y
+6.09 107.98% 3Y
+6.93 144.46% 5Y
-277.87 95.95% 10Y
-167.47 93.45% 20Y
Nasdaq, Closing price Mon, Jul 21 2025
-0.34 2.82%
ISIN
US4884451075
Symbol
ZVRA
Sector
Industry

Key metrics

Basic
Market capitalization
$641.4m
Enterprise Value
$638.9m
Net debt
positive
Cash
$62.6m
Shares outstanding
54.7m
Valuation (TTM | estimate)
P/E
negative | 12.6
P/S
15.8 | 6.9
EV/Sales
15.7 | 6.9
EV/FCF
negative
P/B
15.6
Financial Health
Equity Ratio
22.3%
Return on Equity
-266.0%
ROCE
-49.3%
ROIC
-104.8%
Debt/Equity
1.5
Financials (TTM | estimate)
Revenue
$40.6m | $95.2m
EBITDA
$-65.4m | $-10.4m
EBIT
$-71.9m | $-15.7m
Net Income
$-92.0m | $52.2m
Free Cash Flow
$-67.8m
Growth (TTM | estimate)
Revenue
44.9% | 303.0%
EBITDA
-19.6% | 87.1%
EBIT
-25.7% | 82.0%
Net Income
-80.7% | 149.5%
Free Cash Flow
-47.7%
Margin (TTM | estimate)
Gross
84.4%
EBITDA
-161.1% | -10.9%
EBIT
-177.1%
Net
-226.6% | 54.9%
Free Cash Flow
-167.1%
More
EPS
$-1.7
FCF per Share
$-1.2
Short interest
8.7%
Employees
67
Rev per Employee
$350.0k
Show more

Is KemPharm, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

KemPharm, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a KemPharm, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a KemPharm, Inc. forecast:

Buy
93%
Hold
7%

Financial data from KemPharm, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
41 41
45% 45%
100%
- Direct Costs 6.32 6.32
171% 171%
16%
34 34
139% 139%
84%
- Selling and Administrative Expenses 64 64
74% 74%
159%
- Research and Development Expense 33 33
23% 23%
81%
-65 -65
20% 20%
-161%
- Depreciation and Amortization 6.48 6.48
160% 160%
16%
EBIT (Operating Income) EBIT -72 -72
26% 26%
-177%
Net Profit -92 -92
81% 81%
-227%

In millions USD.

Don't miss a Thing! We will send you all news about KemPharm, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

KemPharm, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced that three posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) and one on OLPRUVA® (sodium phenylbutyrate) are being presented at the 42nd Annual Meeting of the Southeastern Re...
Neutral
GlobeNewsWire
6 days ago
CELEBRATION, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced the publication of “Long-term Efficacy and Safety of Arimoclomol in Niemann-Pick Disease Type C: Final Results of the Phase 2/3 NPC-002 48-month Open-label Extension Trial”...
Neutral
GlobeNewsWire
about 2 months ago
Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D.
More KemPharm, Inc. News

Company Profile

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Head office United States
CEO Neil McFarlane
Employees 67
Founded 2006
Website zevra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today